Soleno grants performance-based RSUs to executives tied to DCCR NDA milestones

SOLENO THERAPEUTICS INC

CEO Anish Bhatnagar receives 850,000 performance-based RSUs; CFO James Mackaness 100,000; SVP Patricia Hirano 85,000.
Vesting: 25% on Aug 1, 2024; 25% on FDA acceptance of DCCR NDA for Prader-Willi syndrome; 50% on FDA approval.
Board increased 2014 Equity Incentive Plan by 2,000,000 shares, approved by 68.6% of votes at June 2024 annual meeting.
Grants aim to bring key employee equity ownership in line with peer group median.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.